INVESTORS
ArrowPress ReleasesArrowInvestor EventsArrowFinancial ReportsArrowSEC FilingsArrowStock InformationArrowCorporate GovernanceArrowInvestor Info
Print Page Print Page | Email Page Email Page | RSS Feeds RSS Feeds | Email Notification Email Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet

Investors

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. AMAG manufactures, Feraheme® (ferumoxytol) Injection for intravenous (IV) use.

In the United States, Feraheme® (ferumoxytol) Injection for intravenous (IV) use received marketing approval from the U.S. Food and Drug Administration on June 30, 2009 and was commercially launched by AMAG in the U.S. shortly thereafter.

Feraheme is indicated for the treatment of iron deficiency anemia in adult chronic kidney disease (CKD) patients.

Feraheme was discovered, developed and is manufactured by AMAG Pharmaceuticals, Inc. For more information about Feraheme, including full prescribing information, please visit www.feraheme.com.